Comparison of two marketed nifedipine modified-release formulations: An exploratory clinical food interaction study

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 48-58

  Wonnemann, Meinolf ^a   Schug, Barbara ^a   Anschütz, Maria ^a   Brendel, Erich ^b   Nucci, Gilberto De ^c   Blume, Henning ^a  

^a SocraTec R and D GmbH   (Germany)

^b BAYER PHARMA AG   (Germany)

^c SocraTec Cartesius   (Brazil)

Author keywords

Bioavailability; Food interaction; Modified release products.; Nifedipine

Indexed keywords

ADALAT OROS; NIFEDIPINA MERCK; NIFEDIPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL LABORATORY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FOOD DRUG INTERACTION; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PH; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET; VALIDATION PROCESS; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIETARY FATS; EATING; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; NIFEDIPINE; SOLUBILITY; TABLETS;

EID: 41949130240     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.001     Document Type: Article

References (30)

1. Waters D. Related articles, links calcium channel blockers: An evidence-based review. Can J Cardiol 13 (1997) 757-766
2. Hedner T. Calcium channel blockers: Spectrum of side effects and drug interactions. Acta Pharmacol Toxicol (Copenh) 58 Suppl 2 (1986) 119-130
3. Investigator's Brochure. BAY a 1040 (Nifedipine), version 7 (December 2000)
4. Foster T., Hamann S., Richards V., et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 23 (1983) 161-170
5. Renwick A., le Vie J., Challenor V., et al. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol 32 (1987) 351-355
6. Reitberg D., Love S., Quercia G., and Zinny M. Effect of food on nifedipine pharmacokinetics. Clin Pharmacol Ther 42 (1987) 72-75
7. Van Harten J., Burggraaf K., Danhof M., et al. Negligible sublingual absorption of nifedipine. Lancet 2 (1987) 1363-1365
8. Renwick A., Robertson D., Macklin B., et al. The pharmacokinetics of oral nifedipinea population study. Br J Clin Pharmacol 25 (1988) 701-708
9. Brown G., Fraser D., Castile J., et al. Nifedipine serum concentrations following sublingual and oral doses. Int J Clin Pharmacol Ther Toxicol 24 (1986) 283-286
10. Kleinbloesem C., van Brummelen P., van de Linde J., et al. Nifedipine: Kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 35 (1984) 742-749
11. Donnelly R., Elliott H., Meredith P., et al. Nifedipine: Individual responses and concentration-effect relationships. Hypertension 12 (1988) 443-449
12. Brown M., Watts M., Mackenzie I., et al. Formulation of long acting nifedipine tablets influences the heart rate and sympathetic nervous response in hypertensive patients. J Hypertens 23 Suppl 2 (2005) S306
13. Taburet A., Singlas E., Colin J., et al. Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects. Hypertension 5 (1983) II29-II33
14. Debbas N., Jackson S., Shah K., et al. The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers. Br J Clin Pharmacol 21 (1986) 385-388
15. Chung M., Reitberg D., Gaffney M., and Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: A controlled-release formulation of nifedipine. Am J Med 83 (1987) 10-14
16. Frishman W., Sherman D., and Feinfeld D. Innovative drug delivery systems in cardiovascular medicine: Nifedipine-GITS and Clonidine-TTS. Cardiol Clin 5 (1987) 703-716
17. Schug B., Brendel E., Chantraine E., et al. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: Pronounced lag-time after a high fat breakfast. Br J Clin Pharmacol 53 (2002) 582-588
18. Schug B., Brendel E., Wolf D., et al. Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur J Pharm Sci 15 (2002) 279-285
19. Schug B., Brendel E., Wonnemann M., et al. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 58 (2002) 119-125
20. Wonnemann M., Schug B., Scmücker K., et al. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union. Int J Clin Pharmacol Ther 44 (2006) 38-48
21. Karim A., Burns T., Wearly L., et al. Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle. Clin Pharmacol Ther 38 (1985) 77-83
22. Karim A., Burns T., Janky D., and Hurwitz A. Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption. Clin Pharmacol Ther 38 (1985) 642-647
23. Brendel. Study no. PHC-PH-PD-P QCD F (2004), Wuppertal, Germany, Bayer Healthcare AG
24. Paddle-Apparatus (USP Apparatus 2), United States Pharmacopeia (USP) XXIII (1995), Rockville, Md 1791-1793
25. European Medicines Agency. ICH Topic E6 (R1) Note for guidance on good clinical practice (CPMP/ICH/ 135/95) (2002)
26. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects and the 52nd WMA General Assembly, Edinburgh, Scotland (October 2000). Note of Clarification on Paragraph 29, Washington 2002; Note of Clarification on Paragraph 30, Tokyo 2004
27. Draft guidance for industry. Bio-analytical method validation (2001), US Dept of Health and Human Services, Food and Drug Administration, CDER, CVM
28. Dos Santos Pereira A. The determination of Nifedipine in Human Plasma by LC-MS/MS using Nimo-dipine as the Internal Standard: GRU 10/04 v01 validation report (2004)
29. Dos Santos Pereira A. The determination of nifedipine in human plasma by LC-MS/MS for the assay GDN 120/04. Analytical report (2004)
30. Note for guidance on modified release oral and transdermal dosage forms. Section II (Pharmacokinetic and clinical evaluation). The European Agency for the evaluation of medicinal products, CPMP/EWP/ 280/96 (1999)